The experimental drug mongersen produced clinical remission in nearly half of patients with Crohn’s disease after 12 weeks of treatment, and an endoscopic response in 37% of those who received the oral agent, according to a study presented at the 2016 United European Gastroenterology Week (abstract LB16).
Gary Lichtenstein, MD, director of the Inflammatory Bowel Disease Center at the Hospital of the University of Pennsylvania, in Philadelphia, who was not involved in the research, called